Varenicline for Smoking Cessation in Light Smokers

被引:16
|
作者
Ebbert, Jon O. [1 ]
Croghan, Ivana T. [1 ]
Hurt, Ryan T. [1 ]
Schroeder, Darrell R. [1 ]
Hays, J. Taylor [1 ]
机构
[1] Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA
关键词
RANDOMIZED CONTROLLED-TRIAL; RECEPTOR PARTIAL AGONIST; FAGERSTROM TOLERANCE QUESTIONNAIRE; SUSTAINED-RELEASE BUPROPION; NICOTINE DEPENDENCE; TOBACCO DEPENDENCE; PLACEBO; ABSTINENCE; EFFICACY; SAFETY;
D O I
10.1093/ntr/ntw123
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Introduction: As the prevalence of cigarette smoking has declined, the proportion of smokers who smoke less than 10 cigarettes/day (cpd) has increased. Varenicline may provide an effective pharmacotherapeutic treatment option for increasing smoking abstinence rates among light smokers. Methods: We conducted a randomized, placebo-controlled clinical trial evaluating the efficacy of varenicline for increasing smoking abstinence rates among light smokers (5-10 cpd). Participants received varenicline or placebo for 12 weeks. Outcomes were assessed at 3 and 6 months. Results: Ninety-three participants were randomized. Fifty-two percent of participants terminated the study early. At end-of-treatment (3 months), the point prevalence smoking abstinence rate was 53.3% in the varenicline group compared to 14.5% in placebo (odds ratio [OR]: 6.69, 95% confidence interval [CI]: 2.48-18.06, P <.001), and the prolonged smoking abstinence rate was 40.0% and 8.3%, respectively (OR: 7.33, 95% CI: 2.24-23.98, P =.001). At end-of-study (6 months), the point prevalence smoking abstinence rate was 40.0% in the varenicline group compared to 20.8% in placebo (OR: 2.53, 95% CI: 1.01-6.34, P =.047), and the prolonged smoking abstinence rate was 31.1% and 8.3%, respectively (OR: 4.97, 95% CI: 1.49-16.53, P =.009). The estimated magnitude of the treatment effect remained consistent across the various missing data assumptions and in analyses that adjusted for gender. Nausea and sleep disturbance were more commonly reported in the varenicline group. Conclusions: Varenicline was safe and effective for increasing long-term smoking abstinence rates in a population of predominantly White light cigarette smoker. The efficacy of varenicline in this study was comparable to that observed in heavier smokers. Implications: Our findings demonstrate that varenicline is effective for increasing smoking cessation in light smokers. Our findings have implications for advancing the treatment of light smokers in clinical practice.
引用
收藏
页码:2031 / 2035
页数:5
相关论文
共 50 条
  • [1] Varenicline Aids Smoking Cessation in Black Smokers
    Slomski, Anita
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (07): : 610 - 610
  • [2] A Pilot Clinical Trial of Varenicline for Smoking Cessation in Black Smokers
    Nollen, Nicole L.
    Cox, Lisa Sanderson
    Nazir, Niaman
    Ellerbeck, Edward F.
    Owen, Ashli
    Pankey, Sydni
    Thompson, Nia
    Ahluwalia, Jasjit S.
    [J]. NICOTINE & TOBACCO RESEARCH, 2011, 13 (09) : 868 - 873
  • [3] Varenicline for smoking cessation
    Harrison-Woolrych, Mira
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
  • [4] Clinical Effectiveness of Varenicline Use for Smoking Cessation in a Sample of Greek Smokers
    Argyropoulou, P.
    Boutou, A. K.
    Stefanidou, E.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [5] Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers
    McColl, S. L.
    Burstein, A. H.
    Reeves, K. R.
    Billing, C. B., Jr.
    Stolar, M.
    Sellers, E. M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (04) : 607 - 614
  • [6] VARENICLINE - A NEW PHARMACOTHERAPY FOR SMOKING CESSATION: IMPLICATION FOR SMOKERS WITH MENTAL HEALTH PROBLEMS
    Robson, Noor Zurani Md Haris
    Rashid, Rusdi Abdul
    Zahari, Muhammad Muhsin Ahmad
    Habil, Mohammad Hussain
    [J]. ASEAN JOURNAL OF PSYCHIATRY, 2009, 10 (02): : 202 - 209
  • [7] Correlates of varenicline adherence among smokers with HIV and its association with smoking cessation
    Quinn, Mackenzie Hosie
    Bauer, Anna-Marika
    Flitter, Alex
    Lubitz, Su Fen
    Ashare, Rebecca L.
    Thompson, Morgan
    Leone, Frank
    Gross, Robert
    Schnoll, Robert
    [J]. ADDICTIVE BEHAVIORS, 2020, 102
  • [8] Experiences of hospitalized smokers initiated on varenicline as part of a pragmatic smoking cessation trial
    Gobarani, Rukshar K.
    Weeks, Gregory R.
    Abramson, Michael J.
    Bonevski, Billie
    Liau, Shin J.
    George, Johnson
    [J]. JOURNAL OF ADDICTIVE DISEASES, 2023, 41 (03) : 242 - 250
  • [9] Effects of Varenicline, Depressive Symptoms, and Region of Enrollment on Smoking Cessation in Depressed Smokers
    Doran, Neal
    Dubrava, Sarah
    Anthenelli, Robert M.
    [J]. NICOTINE & TOBACCO RESEARCH, 2019, 21 (02) : 156 - 162
  • [10] Observational study of safety and efficacy of varenicline for smoking cessation among Filipino smokers
    Park, Peter W.
    Casiano, Errol M.
    Escoto, Laarni
    Claveria, Angelica M.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (10) : 1869 - 1875